source
- Takeda’s ADC arcotatug tavatecan shows survival benefit in phase 3 gastric cancer trialTakeda, together with Innovent Biologics, presented results from a late‑stage study of its next‑generation claudin‑18.2 antibody‑drug conjugate, arcotatug tavatecan (also known as IBI343 or TAK‑921…
- BMS reports patient death in MS CAR-T trial, cites septic pneumonia and pauses enrollmentBMS disclosed details about a patient death that occurred in its investigational CAR-T therapy for multiple sclerosis. The autologous CD19-directed CAR-T, zolacabtagene autoleucel (zola-cel), had…